AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25K 50K 75K Q3 '21: 33K Q4 '21: 50K Q1 '22: 33K Q2 '22: 30K Q3 '22: 21K Q4 '22: 56K Q1 '23: 49K Q2 '23: 42K Q3 '23: 46K Q4 '23: 65K Q1 '24: 40K Q2 '24: 50K Q3 '24: 35K Q4 '24: 45K Q1 '25: 16K Q2 '25: 25K Q3 '25: 26K Q4 '25: 21K Q1 '26: 22K Q2 '26: 26K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -3.9M Q4 '21: -7.4M Q1 '22: -3.2M Q2 '22: -4.7M Q3 '22: -6.5M Q4 '22: -5.6M Q1 '23: -4.3M Q2 '23: -5.5M Q3 '23: -8.2M Q4 '23: -14M Q1 '24: -5.7M Q2 '24: -3.7M Q3 '24: -4.5M Q4 '24: -5.9M Q1 '25: -3.6M Q2 '25: -2.6M Q3 '25: -2.4M Q4 '25: -3M Q1 '26: -2.2M Q2 '26: -3.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -3.8M Q4 '21: -5.8M Q1 '22: -3.8M Q2 '22: -4.9M Q3 '22: -6.4M Q4 '22: -4.4M Q1 '23: -3.7M Q2 '23: -4.9M Q3 '23: -7.8M Q4 '23: -12.6M Q1 '24: -5.8M Q2 '24: -1.8M Q3 '24: -3.7M Q4 '24: -6M Q1 '25: -3.7M Q2 '25: -2.8M Q3 '25: -3.3M Q4 '25: -4.2M Q1 '26: -3M Q2 '26: -3.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 100K 200K 300K Q3 '20: 204K Q4 '20: 198K Q1 '21: 237K Q2 '21: 279K Q3 '21: 157K Q4 '21: 176K Q1 '22: 77K Q2 '22: 69K Q3 '23: 30K Q4 '23: 12K Q1 '24: 8K Q2 '24: 8K Q3 '24: 8K Q4 '24: 7K Q1 '25: 10K Q2 '25: 10K Q3 '25: 68K Q4 '25: 40K Q1 '26: 4K Q2 '26: 5K Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '21: -3.5M Q4 '21: -5.7M Q1 '22: -2.8M Q2 '22: -2.3M Q3 '22: -5M Q4 '22: -6.1M Q1 '23: -3.7M Q2 '23: -2.2M Q3 '23: -5.7M Q4 '23: -9.8M Q1 '24: -4.8M Q2 '24: -3M Q3 '24: -3.1M Q4 '24: -4M Q1 '25: -2.4M Q2 '25: -1.5M Q3 '25: -5.1M Q4 '25: -2M Q1 '26: -2.7M Q2 '26: -4.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '15: -3.5M Q4 '15: -3.3M Q3 '16: -3M Q4 '16: -2.1M Q1 '17: -3M Q2 '17: -2.3M Q3 '17: -1.9M Q4 '17: -760K Q4 '18: -2.4M Q1 '19: -1.5M Q2 '19: -2.8M Q3 '19: -2.5M Q4 '19: -2.3M Q1 '20: -3.3M Q2 '20: -1.3M Q3 '20: -3M Q4 '20: -2.9M Q3 '21: -3.5M Q4 '21: -5.8M Q4 '24: -4M Q4 '15 Q1 '17 Q4 '17 Q2 '19 Q1 '20 Q4 '20 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '22: 48M Q3 '22: 48.1M Q1 '23: 48.4M Q2 '23: 48.4M Q3 '23: 48.6M Q1 '24: 49.5M Q2 '24: 528.4K Q3 '24: 576.8K Q1 '25: 703.3K Q2 '25: 759.3K Q3 '25: 2.1M Q1 '26: 4.4M Q2 '26: 17.1M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '20: 2.12 Q4 '20: -0.50 Q1 '21: -0.36 Q2 '21: -0.37 Q3 '21: -0.37 Q4 '21: -0.40 Q1 '22: -0.40 Q2 '22: -0.38 Q3 '22: -0.43 Q4 '22: -0.40 Q1 '23: -0.40 Q2 '23: -0.40 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.